Journal Home > Volume 13 , Issue 11
Nano Research 2020, 13(11): 2887-2897 https://doi.org/10.1007/s12274-020-2957-8
Review Article | Issue | Published: 16 July 2020

Nanoparticles for targeted cancer radiotherapy

Show Author's Information Roger M. Pallares1,  Rebecca J. Abergel1,2( )
Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
Department of Nuclear Engineering, University of California, Berkeley, CA 94720, USA
Keywords:
nanoparticles, cancer, radiotherapy, targeted cancer radiotherapy, targeted alpha therapy, external beam
Topics:
BiocompatibilityControlled drug deliveryDiseasesDrug interactionsNanoparticlesTargeted drug delivery
Cite this article:
Pallares RM, Abergel RJ. Nanoparticles for targeted cancer radiotherapy. Nano Research, 2020, 13(11): 2887-2897. https://doi.org/10.1007/s12274-020-2957-8
Download citation
EndNote(RIS)
BibTeX

693

Views

36

Downloads

Citations

47

Crossref

N/A

WoS

51

Scopus

3

CSCD

Abstract Full text About this article

Radiotherapy, where ionizing radiation is locally delivered either through an external beam or by surgically implanting radionuclide- based seeds in the tumor, is one of the gold standard treatments for cancer. Due to the non-selective nature of radiation, healthy tissue surrounding the cancerous region is usually affected by the treatment. Hence, new strategies, including targeted alpha therapy, are being studied to improve the selectivity of the treatment and minimize side effects. Several challenges, however, limit the current development of targeted radiotherapy, such as the functionalization of the therapeutic agent with targeting vectors and controlling the release of recoiling daughters. Nanoparticles offer unique opportunities as drug delivery vehicles, since they are biocompatible, enhance the cellular uptake of drugs, and are easily functionalized with targeting molecules. In this review, we examine how nanoparticles can be used for targeted radiotherapy, either as sensitizers of external beams or as delivery vehicles for therapeutic radionuclides. We describe the clinical relevance of different types of nanoparticles, followed by an analysis of how these nanoconstructs can solve some of the main limitations of conventional radiotherapy. Finally, we critically discuss the current situation of nanoparticle-based radiotherapy in clinical settings and challenges that need to be overcome in the future for further development of the field.


menu
Abstract
Full text
Outline
About this article

Nanoparticles for targeted cancer radiotherapy

Show Author's information Roger M. Pallares1, Rebecca J. Abergel1,2( )
Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
Department of Nuclear Engineering, University of California, Berkeley, CA 94720, USA

Abstract

Radiotherapy, where ionizing radiation is locally delivered either through an external beam or by surgically implanting radionuclide- based seeds in the tumor, is one of the gold standard treatments for cancer. Due to the non-selective nature of radiation, healthy tissue surrounding the cancerous region is usually affected by the treatment. Hence, new strategies, including targeted alpha therapy, are being studied to improve the selectivity of the treatment and minimize side effects. Several challenges, however, limit the current development of targeted radiotherapy, such as the functionalization of the therapeutic agent with targeting vectors and controlling the release of recoiling daughters. Nanoparticles offer unique opportunities as drug delivery vehicles, since they are biocompatible, enhance the cellular uptake of drugs, and are easily functionalized with targeting molecules. In this review, we examine how nanoparticles can be used for targeted radiotherapy, either as sensitizers of external beams or as delivery vehicles for therapeutic radionuclides. We describe the clinical relevance of different types of nanoparticles, followed by an analysis of how these nanoconstructs can solve some of the main limitations of conventional radiotherapy. Finally, we critically discuss the current situation of nanoparticle-based radiotherapy in clinical settings and challenges that need to be overcome in the future for further development of the field.

Keywords: nanoparticles, cancer, radiotherapy, targeted cancer radiotherapy, targeted alpha therapy, external beam

References(148)

[1]
Peschel, R. E.; Colberg, J. W. Surgery, brachytherapy, and external- beam radiotherapy for early prostate cancer. Lancet Oncol. 2003, 4, 233-241.
DOI Google Scholar
[2]
Trial, S. R. C. Improved survival with preoperative radiotherapy in resectable rectal cancer. N. Engl. J. Med. 1997, 336, 980-987.
DOI Google Scholar
[3]
Kapiteijn, E.; Marijnen, C. A. M.; Nagtegaal, I. D.; Putter, H.; Steup, W. H.; Wiggers, T.; Rutten, H. J. T.; Pahlman, L.; Glimelius, B.; van Krieken, J. H. J. M. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 2001, 345, 638-646.
DOI Google Scholar
[4]
Bosset, J. F.; Collette, L.; Calais, G.; Mineur, L.; Maingon, P.; Radosevic-Jelic, L.; Daban, A.; Bardet, E.; Beny, A.; Ollier, J. C. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 2006, 355, 1114-1123.
DOI Google Scholar
[5]
Bartelink, H.; Roelofsen, F.; Eschwege, F.; Rougier, P.; Bosset, J. F.; Gonzalez, D. G.; Peiffert, D.; van Glabbeke, M.; Pierart, M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J. Clin. Oncol. 1997, 15, 2040-2049.
DOI Google Scholar
[6]
Ragaz, J.; Jackson, S. M.; Le, N.; Plenderleith, I. H.; Spinelli, J. J.; Basco, V. E.; Wilson, K. S.; Knowling, M. A.; Coppin, C. M. L.; Paradis, M. et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 1997, 337, 956-962.
DOI Google Scholar
[7]
Delaney, G.; Jacob, S.; Featherstone, C.; Barton, M. The role of radiotherapy in cancer treatment. Cancer 2005, 104, 1129-1137.
DOI Google Scholar
[8]
Hoskin, P. J.; Motohashi, K.; Bownes, P.; Bryant, L.; Ostler, P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother. Oncol 2007, 84, 114-120.
DOI Google Scholar
[9]
Joiner, M. C.; Van der Kogel, A. Basic Clinical Radiobiology; CRC Press: Boca Raton, FL, 2009.
DOI
[10]
Bentzen, S. M. Quantitative clinical radiobiology. Acta Oncol. 1993, 32, 259-275.
DOI Google Scholar
[11]
Jaffray, D. A. Image-guided radiotherapy: From current concept to future perspectives. Nat. Rev. Clin. Oncol. 2012, 9, 688-699.
DOI Google Scholar
[12]
Morris, Z. S.; Harari, P. M. Interaction of radiation therapy with molecular targeted agents. J. Clin. Oncol. 2014, 32, 2886-2893.
DOI Google Scholar
[13]
Sun, H. N.; Wang, X. L.; Zhai, S. M. The rational design and biological mechanisms of nanoradiosensitizers. Nanomaterials 2020, 10, 504.
DOI Google Scholar
[14]
Boateng, F.; Ngwa, W. Delivery of nanoparticle-based radiosensitizers for radiotherapy applications. Int. J. Mol. Sci. 2020, 21, 273.
DOI Google Scholar
[15]
Xie, D.; Wang, M. P.; Qi, W. H. A simplified model to calculate the surface-to-volume atomic ratio dependent cohesive energy of nanocrystals. J. Phys.: Condens. Matter 2004, 16, L401-L405.
DOI Google Scholar
[16]
Pallares, R. M.; Choo, P.; Cole, L. E.; Mirkin, C. A.; Lee, A.; Odom, T. W. Manipulating immune activation of macrophages by tuning the oligonucleotide composition of gold nanoparticles. Bioconjugate Chem. 2019, 30, 2032-2037.
DOI Google Scholar
[17]
Patel, P. C.; Giljohann, D. A.; Daniel, W. L.; Zheng, D.; Prigodich, A. E.; Mirkin, C. A. Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. Bioconjugate Chem. 2010, 21, 2250-2256.
DOI Google Scholar
[18]
Engels, E.; Westlake, M.; Li, N.; Vogel, S.; Gobert, Q.; Thorpe, N.; Rosenfeld, A.; Lerch, M.; Corde, S.; Tehei, M. Thulium oxide nanoparticles: A new candidate for image-guided radiotherapy. Biomed. Phys. Eng. Exp. 2018, 4, 044001.
DOI Google Scholar
[19]
Yue, J.; Pallares, R. M.; Cole, L. E.; Coughlin, E. E.; Mirkin, C. A.; Lee, A.; Odom, T. W. Smaller CpG-conjugated gold nanoconstructs achieve higher targeting specificity of immune activation. ACS Appl. Mater. Interfaces 2018, 10, 21920-21926.
DOI Google Scholar
[20]
Pallares, R. M.; Kong, S. L.; Ru, T. H.; Thanh, N. T. K.; Lu, Y.; Su, X. D. A plasmonic nanosensor with inverse sensitivity for circulating cell-free DNA quantification. Chem. Commun. 2015, 51, 14524-14527.
DOI Google Scholar
[21]
Lu, A. H.; Salabas, E. L.; Schüth, F. Magnetic nanoparticles: Synthesis, protection, functionalization, and application. Angew. Chem., Int. Ed. 2007, 46, 1222-1244.
DOI Google Scholar
[22]
Pallares, R. M.; Thanh, N. T. K.; Su, X. D. Tunable plasmonic colorimetric assay with inverse sensitivity for extracellular DNA quantification. Chem. Commun. 2018, 54, 11260-11263.
DOI Google Scholar
[23]
Sedlmeier, A.; Gorris, H. H. Surface modification and characterization of photon-upconverting nanoparticles for bioanalytical applications. Chem. Soc. Rev. 2015, 44, 1526-1560.
DOI Google Scholar
[24]
Pallares, R. M.; Thanh, N. T. K.; Su, X. D. Quantifying the binding between proteins and open chromatin-like DNA sequences with gold nanorods. Chem. Commun. 2019, 55, 15041-15044.
DOI Google Scholar
[25]
Pallares, R. M.; Carter, K. P.; Zeltmann, S. E.; Tratnjek, T.; Minor, A. M.; Abergel, R. J. Selective lanthanide sensing with gold nanoparticles and hydroxypyridinone chelators. Inorg. Chem. 2020, 59, 2030-2036.
DOI Google Scholar
[26]
Pallares, R. M.; Bosman, M.; Thanh, N. T. K.; Su, X. D. A plasmonic multi-logic gate platform based on sequence-specific binding of estrogen receptors and gold nanorods. Nanoscale 2016, 8, 19973-19977.
DOI Google Scholar
[27]
Wu, P. H.; Onodera, Y.; Ichikawa, Y.; Rankin, E. B.; Giaccia, A. J.; Watanabe, Y.; Qian, W.; Hashimoto, T.; Shirato, H.; Nam, J. M. Targeting integrins with RGD-conjugated gold nanoparticles in radiotherapy decreases the invasive activity of breast cancer cells. Int. J. Nanomedicine 2017, 12, 5069-5085.
DOI Google Scholar
[28]
Du, F. Y.; Lou, J. M.; Jiang, R.; Fang, Z. Z.; Zhao, X. F.; Niu, Y. Y.; Zou, S. Q.; Zhang, M. M.; Gong, A. H.; Wu, C. Y. Hyaluronic acid- functionalized bismuth oxide nanoparticles for computed tomography imaging-guided radiotherapy of tumor. Int. J. Nanomedicine 2017, 12, 5973-5992.
DOI Google Scholar
[29]
Huynh, N. T.; Roger, E.; Lautram, N.; Benoît, J. P.; Passirani, C. The rise and rise of stealth nanocarriers for cancer therapy: Passive versus active targeting. Nanomedicine 2010, 5, 1415-1433.
DOI Google Scholar
[30]
Rabanel, J. M.; Aoun, V.; Elkin, I.; Mokhtar, M.; Hildgen, P. Drug- loaded nanocarriers: Passive targeting and crossing of biological barriers. Curr. Med. Chem. 2012, 19, 3070-3102.
DOI Google Scholar
[31]
Pallares, R. M.; Su, X. D.; Lim, S. H.; Thanh, N. T. K. Fine-tuning of gold nanorod dimensions and plasmonic properties using the Hofmeister effects. J. Mater. Chem. C 2016, 4, 53-61.
DOI Google Scholar
[32]
Pallares, R. M.; Wang, Y. S.; Lim, S. H.; Thanh, N. T. K.; Su, X. D. Growth of anisotropic gold nanoparticles in photoresponsive fluid for UV sensing and erythema prediction. Nanomedicine 2016, 11, 2845-2860.
Google Scholar
[33]
Pallares, R. M.; Stilson, T.; Choo, P.; Hu, J. T.; Odom, T. W. Using good’s buffers to control the anisotropic structure and optical properties of spiky gold nanoparticles for refractive index sensing. ACS Appl. Nano Mater. 2019, 2, 5266-5271.
DOI Google Scholar
[34]
Haase, M.; Schäfer, H. Upconverting nanoparticles. Angew. Chem., Int. Ed. 2011, 50, 5808-5829.
DOI Google Scholar
[35]
Alkilany, A. M.; Thompson, L. B.; Boulos, S. P.; Sisco, P. N.; Murphy, C. J. Gold nanorods: Their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions. Adv. Drug Deliv. Rev. 2012, 64, 190-199.
DOI Google Scholar
[36]
Mansoori, G. A.; Mohazzabi, P.; McCormack, P.; Jabbari, S. Nanotechnology in cancer prevention, detection and treatment: Bright future lies ahead. World Rev. Sci., Technol. Sustain. Dev. 2007, 4, 226-257.
DOI Google Scholar
[37]
Du, J. F.; Gu, Z. J.; Yan, L.; Yong, Y.; Yi, X.; Zhang, X.; Liu, J.; Wu, R. F.; Ge, C. C.; Chen, C. Y. et al. Poly(vinylpyrollidone)- and selenocysteine-modified Bi2Se3 nanoparticles enhance radiotherapy efficacy in tumors and promote radioprotection in normal tissues. Adv. Mater. 2017, 29, 1701268.
DOI Google Scholar
[38]
Murphy, C. J.; Sau, T. K.; Gole, A. M.; Orendorff, C. J.; Gao, J. X.; Gou, L. F.; Hunyadi, S. E.; Li, T. Anisotropic metal nanoparticles: Synthesis, assembly, and optical applications. J. Phys. Chem. B 2005, 109, 13857-13870.
DOI Google Scholar
[39]
Pérez-Juste, J.; Pastoriza-Santos, I.; Liz-Marzán, L. M.; Mulvaney, P. Gold nanorods: Synthesis, characterization and applications. Coord. Chem. Rev. 2005, 249, 1870-1901.
Google Scholar
[40]
Mourdikoudis, S.; Pallares, R. M.; Thanh, N. T. K. Characterization techniques for nanoparticles: Comparison and complementarity upon studying nanoparticle properties. Nanoscale 2018, 10, 12871-12934.
DOI Google Scholar
[41]
Pallares, R. M.; Thanh, N. T. K.; Su, X. D. Sensing of circulating cancer biomarkers with metal nanoparticles. Nanoscale 2019, 11, 22152-22171.
DOI Google Scholar
[42]
Pallares, R. M.; Abergel, R. J. Transforming lanthanide and actinide chemistry with nanoparticles. Nanoscale 2020, 12, 1339-1348.
DOI Google Scholar
[43]
Li, N.; Su, X. D.; Lu, Y. Nanomaterial-based biosensors using dual transducing elements for solution phase detection. Analyst 2015, 140, 2916-2943.
DOI Google Scholar
[44]
Pankhurst, Q. A.; Connolly, J.; Jones, S. K.; Dobson, J. Applications of magnetic nanoparticles in biomedicine. J. Phys. D: Appl. Phys. 2003, 36, R167-R181.
DOI Google Scholar
[45]
Ren, X. C.; Liu, Y. E.; Li, J.; Lin, Q. Progress in image-guided radiotherapy for the treatment of non-small cell lung cancer. World J. Radiol. 2019, 11, 46-54.
DOI Google Scholar
[46]
L'Annunziata, M. F. Chapter 1 - Radioactivity and our well-being. In Radioactivity; 2nd ed. L'Annunziata, M. F., Ed.; Elsevier: Boston, 2016; pp 1-66.
DOI
[47]
Amols, H. I.; Lagueux, B.; Cagna, D. Radiobiological effectiveness (RBE) of megavoltage X-ray and electron beams in radiotherapy. Radiat. Res. 1986, 105, 58-67.
DOI Google Scholar
[48]
Smith, R.; Davidson, J. K.; Flatman, G. E. Skeletal effects of orthovoltage and megavoltage therapy following treatment of nephroblastoma. Clin. Radiol. 1982, 33, 601-613.
DOI Google Scholar
[49]
Eastman, R. C.; Görden, P.; Glatstein, E.; Roth, J. Radiation therapy of acromegaly. Endocrinol. Metab. Clin. North Am. 1992, 21, 693-712.
DOI Google Scholar
[50]
Mohan, R.; Grosshans, D. Proton therapy—Present and future. Adv. Drug Deliv. Rev. 2017, 109, 26-44.
DOI Google Scholar
[51]
Laprise-Pelletier, M.; Simão, T.; Fortin, M. A. Gold nanoparticles in radiotherapy and recent progress in nanobrachytherapy. Adv. Healthc. Mater. 2018, 7, 1701460.
DOI Google Scholar
[52]
Anholt, R.; Rasmussen, J. O. Theoretical X-ray transition probabilities for high-Z superheavy elements. Phys. Rev. A 1974, 9, 585-592.
DOI Google Scholar
[53]
Seibert, J. A.; Boone, J. M. X-ray imaging physics for nuclear medicine technologists. Part 2: X-ray interactions and image formation. J. Nucl. Med. Technol. 2005, 33, 3-18.
Google Scholar
[54]
Ebel, H.; Svagera, R.; Ebel, M. F.; Shaltout, A.; Hubbell, J. H. Numerical description of photoelectric absorption coefficients for fundamental parameter programs. X-Ray Spectrom. 2003, 32, 442-451.
DOI Google Scholar
[55]
Yokoya, A.; Shikazono, N.; Fujii, K.; Urushibara, A.; Akamatsu, K.; Watanabe, R. DNA damage induced by the direct effect of radiation. Radiat. Phys. Chem. 2008, 77, 1280-1285.
DOI Google Scholar
[56]
Karnas, S. J.; Moiseenko, V. V.; Yu, E.; Truong, P.; Battista, J. J. Monte Carlo simulations and measurement of DNA damage from X-ray-triggered Auger cascades in iododeoxyuridine (IUdR). Radiat. Environ. Biophys. 2001, 40, 199-206.
DOI Google Scholar
[57]
Hainfeld, J. F.; Ridwan, S. M.; Stanishevskiy, Y.; Panchal, R.; Slatkin, D. N.; Smilowitz, H. M. Iodine nanoparticles enhance radiotherapy of intracerebral human glioma in mice and increase efficacy of chemotherapy. Sci. Rep. 2019, 9, 4505.
DOI Google Scholar
[58]
Moeller, B. J.; Richardson, R. A.; Dewhirst, M. W. Hypoxia and radiotherapy: Opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007, 26, 241-248.
DOI Google Scholar
[59]
Song, G. S.; Liang, C.; Yi, X.; Zhao, Q.; Cheng, L.; Yang, K.; Liu, Z. Perfluorocarbon-loaded hollow Bi2Se3 nanoparticles for timely supply of oxygen under near-infrared light to enhance the radiotherapy of cancer. Adv. Mater. 2016, 28, 2716-2723.
DOI Google Scholar
[60]
Li, Y.; Yun, K. H.; Lee, H.; Goh, S. H.; Suh, Y. G.; Choi, Y. Porous platinum nanoparticles as a high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo. Biomaterials 2019, 197, 12-19.
DOI Google Scholar
[61]
Fan, W. P.; Bu, W. B.; Zhang, Z.; Shen, B.; Zhang, H.; He, Q. J.; Ni, D. L.; Cui, Z. W.; Zhao, K. L.; Bu, J. W. et al. X-ray radiation- controlled NO-release for on-demand depth-independent hypoxic radiosensitization. Angew. Chem., Int. Ed. 2015, 54, 14026-14030.
DOI Google Scholar
[62]
Fan, W. P.; Lu, N.; Shen, Z. Y.; Tang, W.; Shen, B.; Cui, Z. W.; Shan, L. L.; Yang, Z.; Wang, Z. T.; Jacobson, O. et al. Generic synthesis of small-sized hollow mesoporous organosilica nanoparticles for oxygen- independent X-ray-activated synergistic therapy. Nat. Commun 2019, 10, 1241.
DOI Google Scholar
[63]
Goswami, N.; Luo, Z. T.; Yuan, X.; Leong, D. T.; Xie, J. P. Engineering gold-based radiosensitizers for cancer radiotherapy. Mater. Horiz. 2017, 4, 817-831.
DOI Google Scholar
[64]
Zeng, S. W.; Yong, K. T.; Roy, I.; Dinh, X. Q.; Yu, X.; Luan, F. A review on functionalized gold nanoparticles for biosensing applications. Plasmonics 2011, 6, 491.
DOI Google Scholar
[65]
Han, G.; Ghosh, P.; Rotello, V. M. Functionalized gold nanoparticles for drug delivery. Nanomedicine 2007, 2, 113-123.
DOI Google Scholar
[66]
Luo, D.; Wang, X. N.; Zeng, S.; Ramamurthy, G.; Burda, C.; Basilion, J. P. Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: Does size matter for targeted particles? Chem. Sci. 2019, 10, 8119-8128.
DOI Google Scholar
[67]
Ma, N. N.; Wu, F. G.; Zhang, X. D.; Jiang, Y. W.; Jia, H. R.; Wang, H. Y.; Li, Y. H.; Liu, P. D.; Gu, N.; Chen, Z. Shape-dependent radiosensitization effect of gold nanostructures in cancer radiotherapy: Comparison of gold nanoparticles, nanospikes, and nanorods. ACS Appl. Mater. Interfaces 2017, 9, 13037-13048.
DOI Google Scholar
[68]
Fathy, M. M.; Mohamed, F. S.; Elbialy, N. S.; Elshemey, W. M. Multifunctional chitosan-capped gold nanoparticles for enhanced cancer chemo-radiotherapy: An in vitro study. Phys. Med. 2018, 48, 76-83.
DOI Google Scholar
[69]
Yi, X.; Chen, L.; Chen, J.; Maiti, D.; Chai, Z. F.; Liu, Z.; Yang, K. Biomimetic copper sulfide for chemo-radiotherapy: Enhanced uptake and reduced efflux of nanoparticles for tumor cells under ionizing radiation. Adv. Funct. Mater. 2018, 28, 1705161.
DOI Google Scholar
[70]
Butterworth, K. T.; Nicol, J. R.; Ghita, M.; Rosa, S.; Chaudhary, P.; McGarry, C. K.; McCarthy, H. O.; Jimenez-Sanchez, G.; Bazzi, R.; Roux, S. et al. Preclinical evaluation of gold-DTDTPA nanoparticles as theranostic agents in prostate cancer radiotherapy. Nanomedicine 2016, 11, 2035-2047.
DOI Google Scholar
[71]
Dou, Y.; Guo, Y. Y.; Li, X. D.; Li, X.; Wang, S.; Wang, L.; Lv, G. X.; Zhang, X. N.; Wang, H. J.; Gong, X. Q. et al. Size-tuning ionization to optimize gold nanoparticles for simultaneous enhanced CT imaging and radiotherapy. ACS Nano 2016, 10, 2536-2548.
DOI Google Scholar
[72]
Mignot, A.; Truillet, C.; Lux, F.; Sancey, L.; Louis, C.; Denat, F.; Boschetti, F.; Bocher, L.; Gloter, A.; Stéphan, O. et al. A top-down synthesis route to ultrasmall multifunctional Gd-based silica nanoparticles for theranostic applications. Chem.-Eur. J. 2013, 19, 6122-6136.
DOI Google Scholar
[73]
Detappe, A.; Kunjachan, S.; Sancey, L.; Motto-Ros, V.; Biancur, D.; Drane, P.; Guieze, R.; Makrigiorgos, G. M.; Tillement, O.; Langer, R. et al. Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy. J. Control. Release 2016, 238, 103-113.
DOI Google Scholar
[74]
Peukert, D.; Kempson, I.; Douglass, M.; Bezak, E. Metallic nanoparticle radiosensitisation of ion radiotherapy: A review. Phys. Med. 2018, 47, 121-128.
DOI Google Scholar
[75]
Liu, C. J.; Wang, C. H.; Chen, S. T.; Chen, H. H.; Leng, W. H.; Chien, C. C.; Wang, C. L.; Kempson, I. M.; Hwu, Y.; Lai, T. C. et al. Enhancement of cell radiation sensitivity by pegylated gold nanoparticles. Phys. Med. Biol. 2010, 55, 931-945.
DOI Google Scholar
[76]
Polf, J. C.; Bronk, L. F.; Driessen, W. H. P.; Arap, W.; Pasqualini, R.; Gillin, M. Enhanced relative biological effectiveness of proton radiotherapy in tumor cells with internalized gold nanoparticles. Appl. Phys. Lett. 2011, 98, 193702.
DOI Google Scholar
[77]
Schlathölter, T.; Eustache, P.; Porcel, E.; Salado, D.; Stefancikova, L.; Tillement, O.; Lux, F.; Mowat, P.; Biegun, A. K.; van Goethem, M. J. et al. Improving proton therapy by metal-containing nanoparticles: Nanoscale insights. Int. J. Nanomedicine 2016, 11, 1549-1556.
DOI Google Scholar
[78]
Kim, J. K.; Seo, S. J.; Kim, H. T.; Kim, K. H.; Chung, M. H.; Kim, K. R.; Ye, S. J. Enhanced proton treatment in mouse tumors through proton irradiated nanoradiator effects on metallic nanoparticles. Phys. Med. Biol. 2012, 57, 8309-8323.
DOI Google Scholar
[79]
Li, S.; Bouchy, S.; Penninckx, S.; Marega, R.; Fichera, O.; Gallez, B.; Feron, O.; Martinive, P.; Heuskin, A. C.; Michiels, C. et al. Antibody-functionalized gold nanoparticles as tumor-targeting radiosensitizers for proton therapy. Nanomedicine 2019, 14, 317-333.
DOI Google Scholar
[80]
Heuskin, A. C.; Gallez, B.; Feron, O.; Martinive, P.; Michiels, C.; Lucas, S. Metallic nanoparticles irradiated by low-energy protons for radiation therapy: Are there significant physical effects to enhance the dose delivery? Med. Phys. 2017, 44, 4299-4312.
DOI Google Scholar
[81]
Martínez-Rovira, I.; Prezado, Y. Evaluation of the local dose enhancement in the combination of proton therapy and nanoparticles. Med. Phys. 2015, 42, 6703-6710.
DOI Google Scholar
[82]
Lin, Y. T.; Paganetti, H.; McMahon, S. J.; Schuemann, J. Gold nanoparticle induced vasculature damage in radiotherapy: Comparing protons, megavoltage photons, and kilovoltage photons. Med. Phys. 2015, 42, 5890-5902.
DOI Google Scholar
[83]
Penninckx, S.; Heuskin, A. C.; Michiels, C.; Lucas, S. The role of thioredoxin reductase in gold nanoparticle radiosensitization effects. Nanomedicine 2018, 13, 2917-2937.
DOI Google Scholar
[84]
Soloway, A. H.; Tjarks, W.; Barnum, B. A.; Rong, F. G.; Barth, R. F.; Codogni, I. M.; Wilson, J. G. The chemistry of neutron capture therapy. Chem. Rev. 1998, 98, 1515-1562.
DOI Google Scholar
[85]
Hawthorne, M. F. The role of chemistry in the development of boron neutron capture therapy of cancer. Angew. Chem., Int. Ed. 1993, 32, 950-984.
DOI Google Scholar
[86]
Barth, R. F.; Coderre, J. A.; Vicente, M. G. H.; Blue, T. E. Boron neutron capture therapy of cancer: Current status and future prospects. Clin. Cancer Res. 2005, 11, 3987-4002.
DOI Google Scholar
[87]
Frederick Hawthorne, M.; Lee, M. W. A critical assessment of boron target compounds for boron neutron capture therapy. J. Neuro-Oncol. 2003, 62, 33-45.
DOI Google Scholar
[88]
Kobayashi, T.; Kanda, K. Analytical calculation of boron-10 dosage in cell nucleus for neutron capture therapy. Radiat. Res. 1982, 91, 77-94.
DOI Google Scholar
[89]
Barth, R. F.; Vicente, M. G. H.; Harling, O. K.; Kiger III, W. S.; Riley, K. J.; Binns, P. J.; Wagner, F. M.; Suzuki, M.; Aihara, T.; Kato, I. et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat. Oncol. 2012, 7, 146.
DOI Google Scholar
[90]
Moss, R. L. Critical review, with an optimistic outlook, on boron neutron capture therapy (BNCT). Appl. Radiat. Isot. 2014, 88, 2-11.
DOI Google Scholar
[91]
Takeuchi, I.; Nomura, K.; Makino, K. Hydrophobic boron compound- loaded poly(l-lactide-co-glycolide) nanoparticles for boron neutron capture therapy. Colloids Surf. B: Biointerfaces 2017, 159, 360-365.
DOI Google Scholar
[92]
Wu, C. Y.; Lin, J. J.; Chang, W. Y.; Hsieh, C. Y.; Wu, C. C.; Chen, H. S.; Hsu, H. J.; Yang, A. S.; Hsu, M. H.; Kuo, W. Y. Development of theranostic active-targeting boron-containing gold nanoparticles for boron neutron capture therapy (BNCT). Colloids Surf. B: Biointerfaces 2019, 183, 110387.
DOI Google Scholar
[93]
Gao, Z. Y.; Horiguchi, Y.; Nakai, K.; Matsumura, A.; Suzuki, M.; Ono, K.; Nagasaki, Y. Use of boron cluster-containing redox nanoparticles with ROS scavenging ability in boron neutron capture therapy to achieve high therapeutic efficiency and low adverse effects. Biomaterials 2016, 104, 201-212.
DOI Google Scholar
[94]
Kuthala, N.; Vankayala, R.; Li, Y. N.; Chiang, C. S.; Hwang, K. C. Engineering novel targeted boron-10-enriched theranostic nanomedicine to combat against murine brain tumors via MR imaging-guided boron neutron capture therapy. Adv. Mater. 2017, 29, 1700850.
DOI Google Scholar
[95]
Deutsch, O. L.; Murray, B. W. Monte Carlo dosimetry calculation for boron neutron-capture therapy in the treatment of brain tumors. Nucl. Technol. 1975, 26, 320-339.
DOI Google Scholar
[96]
Kanda, K.; Kobayashi, T.; Ono, K.; Sato, T.; Shibata, T.; Ueno, Y.; Mishima, Y.; Hatanaka, H.; Nishiwaki, Y. Elimination of gamma rays from a thermal neutron field for medical and biological irradiation purposes, biological dosimetry. IAEA-SM-193/168, 1975.
[97]
Leach, J. K.; Van Tuyle, G.; Lin, P. S.; Schmidt-Ullrich, R.; Mikkelsen, R. B. Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen. Cancer Res. 2001, 61, 3894-3901.
Google Scholar
[98]
Salt, C.; Lennox, A. J.; Takagaki, M.; Maguire, J. A.; Hosmane, N. S. Boron and gadolinium neutron capture therapy. Russ. Chem. Bull. 2004, 53, 1871-1888.
DOI Google Scholar
[99]
Dorozhkin, S. V.; Epple, M. Biological and medical significance of calcium phosphates. Angew. Chem., Int. Ed. 2002, 41, 3130-3146.
DOI
[100]
Dewi, N.; Mi, P.; Yanagie, H.; Sakurai, Y.; Morishita, Y.; Yanagawa, M.; Nakagawa, T.; Shinohara, A.; Matsukawa, T.; Yokoyama, K. et al. In vivo evaluation of neutron capture therapy effectivity using calcium phosphate-based nanoparticles as Gd-DTPA delivery agent. J. Cancer Res. Clin. Oncol. 2016, 142, 767-775.
DOI Google Scholar
[101]
Ghithan, S.; Roy, G.; Schuh, S. Design study of beam transport lines for BioLEIR facility at CERN. J. Instrum. 2017, 12, P09019.
DOI Google Scholar
[102]
Suit, H.; DeLaney, T.; Goldberg, S.; Paganetti, H.; Clasie, B.; Gerweck, L.; Niemierko, A.; Hall, E.; Flanz, J.; Hallman, J. et al. Proton vs. carbon ion beams in the definitive radiation treatment of cancer patients. Radiother. Oncol. 2010, 95, 3-22.
DOI Google Scholar
[103]
Kaur, H.; Pujari, G.; Semwal, M. K.; Sarma, A.; Avasthi, D. K. In vitro studies on radiosensitization effect of glucose capped gold nanoparticles in photon and ion irradiation of HeLa cells. Nucl. Instrum. Meth. Phys. Res. Section B: Beam Int. Mater. Atoms 2013, 301, 7-11.
DOI Google Scholar
[104]
Liu, Y.; Liu, X.; Jin, X. D.; He, P. B.; Zheng, X. G.; Ye, F.; Chen, W. Q.; Li, Q. The radiation enhancement of 15 nm citrate-capped gold nanoparticles exposed to 70 keV/μm carbon ions. J. Nanosci. Nanotechnol. 2016, 16, 2365-2370.
DOI Google Scholar
[105]
Dale, R. G.; Jones, B. The clinical radiobiology of brachytherapy. Br. J. Radiol. 1998, 71, 465-483.
DOI Google Scholar
[106]
Tanderup, K.; Ménard, C.; Polgar, C.; Lindegaard, J. C.; Kirisits, C.; Pötter, R. Advancements in brachytherapy. Adv. Drug Deliv. Rev. 2017, 109, 15-25.
DOI Google Scholar
[107]
Rivard, M. J.; Coursey, B. M.; DeWerd, L. A.; Hanson, W. F.; Huq, M. S.; Ibbott, G. S.; Mitch, M. G.; Nath, R.; Williamson, J. F. Update of the AAPM task group No. 43 report—A revised AAPM protocol for brachytherapy dose calculations. Int. J. Radiat. Oncol. Biol. Phys. 2003, 57, S430.
DOI Google Scholar
[108]
Kee, D. L. C.; Gal, J.; Falk, A. T.; Schiappa, R.; Chand, M. E.; Gautier, M.; Doyen, J.; Hannoun-Levi, J. M. Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials. Cancer Treat. Rev. 2018, 70, 265-271.
DOI Google Scholar
[109]
Dicker, A. P.; Merrick, G. S.; Waterman, F. M.; Valicenti, R. K.; Gomella, L. G. Basic and Advanced Techniques in Prostate Brachytherapy; CRC Press: Boca Raton, FL, 2005.
DOI
[110]
Elgqvist, J.; Frost, S.; Pouget, J. P.; Albertsson, P. The potential and hurdles of targeted alpha therapy—Clinical trials and beyond. Front. Oncol. 2014, 3, 324.
DOI Google Scholar
[111]
Olafsen, T.; Elgqvist, J.; Wu, A. M. Protein targeting constructs in Alpha Therapy. Curr. Radiopharm. 2011, 4, 197-213.
DOI Google Scholar
[112]
Sharkey, R. M.; Goldenberg, D. M. Cancer radioimmunotherapy. Immunotherapy 2011, 3, 349-370.
DOI Google Scholar
[113]
Couturier, O.; Supiot, S.; Degraef-Mougin, M.; Faivre-Chauvet, A.; Carlier, T.; Chatal, J. F.; Davodeau, F.; Cherel, M. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 601-614.
DOI Google Scholar
[114]
Dong, C.; Liu, Z.; Wang, F. Peptide-based radiopharmaceuticals for targeted tumor therapy. Curr. Med. Chem. 2014, 21, 139-152.
DOI Google Scholar
[115]
Pool, S. E.; Krenning, E. P.; Koning, G. A.; van Eijck, C. H. J.; Teunissen, J. J. M.; Kam, B.; Valkema, R.; Kwekkeboom, D. J.; de Jong, M. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin. Nucl. Med. 2010, 40, 209-218.
DOI Google Scholar
[116]
Müller, C.; Schibli, R. Prospects in folate receptor-targeted radionuclide therapy. Front. Oncol. 2013, 3, 249.
DOI Google Scholar
[117]
Qhobosheane, M.; Santra, S.; Zhang, P.; Tan, W. H. Biochemically functionalized silica nanoparticles. Analyst 2001, 126, 1274-1278.
DOI Google Scholar
[118]
Dreaden, E. C.; Alkilany, A. M.; Huang, X. H.; Murphy, C. J.; El-Sayed, M. A. The golden age: Gold nanoparticles for biomedicine. Chem. Soc. Rev. 2012, 41, 2740-2779.
DOI Google Scholar
[119]
Radovic-Moreno, A. F.; Chernyak, N.; Mader, C. C.; Nallagatla, S.; Kang, R. S.; Hao, L. L.; Walker, D. A.; Halo, T. L.; Merkel, T. J.; Rische, C. H. et al. Immunomodulatory spherical nucleic acids. Proc. Natl. Acad. Sci. 2015, 112, 3892-3897.
DOI Google Scholar
[120]
Laprise-Pelletier, M.; Lagueux, J.; Côté, M. F.; LaGrange, T.; Fortin, M. A. Low-dose prostate cancer brachytherapy with radioactive palladium-gold nanoparticles. Adv. Healthc. Mater. 2017, 6, 1601120.
DOI Google Scholar
[121]
Lacoeuille, F.; Arlicot, N.; Faivre-Chauvet, A. Targeted alpha and beta radiotherapy: An overview of radiopharmaceutical and clinical aspects. Méd. Nucl. 2018, 42, 32-44.
DOI Google Scholar
[122]
De Kruijff, M. R.; Wolterbeek, T. H.; Denkova, G. A. A critical review of alpha radionuclide therapy—How to deal with recoiling daughters? Pharmaceuticals 2015, 8, 321-336.
DOI Google Scholar
[123]
Kannan, R.; Zambre, A.; Chanda, N.; Kulkarni, R.; Shukla, R.; Katti, K.; Upendran, A.; Cutler, C.; Boote, E.; Katti, K. V. Functionalized radioactive gold nanoparticles in tumor therapy. WIREs Nanomedicine Nanobiotechnol. 2012, 4, 42-51.
DOI Google Scholar
[124]
Al-Yasiri, A. Y.; Khoobchandani, M.; Cutler, C. S.; Watkinson, L.; Carmack, T.; Smith, C. J.; Kuchuk, M.; Loyalka, S. K.; Lugão, A. B.; Katti, K. V. Mangiferin functionalized radioactive gold nanoparticles (MGF-198AuNPs) in prostate tumor therapy: Green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy. Dalton Trans. 2017, 46, 14561-14571.
DOI Google Scholar
[125]
Chakravarty, R.; Chakraborty, S.; Guleria, A.; Shukla, R.; Kumar, C.; Vimalnath Nair, K. V.; Sarma, H. D.; Tyagi, A. K.; Dash, A. Facile one-pot synthesis of intrinsically radiolabeled and cyclic RGD conjugated 199Au nanoparticles for potential use in nanoscale brachytherapy. Ind. Eng. Chem. Res. 2018, 57, 14337-14346.
DOI Google Scholar
[126]
Al-Yasiri, A. Y.; White, N. E.; Katti, K. V.; Loyalka, S. K. Estimation of tumor and local tissue dose in gold nanoparticles radiotherapy for prostate cancer. Rep. Pract. Oncol. Radiother. 2019, 24, 288-293.
DOI Google Scholar
[127]
Fazaeli, Y.; Akhavan, O.; Rahighi, R.; Aboudzadeh, M. R.; Karimi, E.; Afarideh, H. In vivo SPECT imaging of tumors by 198,199Au- labeled graphene oxide nanostructures. Mater. Sci. Eng.: C 2014, 45, 196-204.
DOI Google Scholar
[128]
Dash, A.; Pillai, M. R. A.; Knapp, F. F. Production of 177Lu for targeted radionuclide therapy: Available options. Nucl. Med. Mol. Imaging 2015, 49, 85-107.
DOI Google Scholar
[129]
Yook, S.; Cai, Z. L.; Lu, Y. J.; Winnik, M. A.; Pignol, J. P.; Reilly, R. M. Intratumorally injected 177Lu-labeled gold nanoparticles: Gold nanoseed brachytherapy with application for neoadjuvant treatment of locally advanced breast cancer. J. Nucl. Med. 2016, 57, 936-942.
DOI Google Scholar
[130]
Yu, B.; Wei, H.; He, Q. J.; Ferreira, C. A.; Kutyreff, C. J.; Ni, D. L.; Rosenkrans, Z. T.; Cheng, L.; Yu, F. Q.; Engle, J. W. et al. Efficient uptake of 177Lu-porphyrin-PEG nanocomplexes by tumor mitochondria for multimodal-imaging-guided combination therapy. Angew. Chem., Int. Ed. 2018, 57, 218-222.
DOI Google Scholar
[131]
Yu, B.; Ni, D. L.; Rosenkrans, Z. T.; Barnhart, T. E.; Wei, H.; Ferreira, C. A.; Lan, X. L.; Engle, J. W.; He, Q. J.; Yu, F. Q. et al. A “missile-detonation” strategy to precisely supply and efficiently amplify cerenkov radiation energy for cancer theranostics. Adv. Mater. 2019, 31, 1904894.
DOI Google Scholar
[132]
Meng, Z. Q.; Chao, Y.; Zhou, X. F.; Liang, C.; Liu, J. J.; Zhang, R.; Cheng, L.; Yang, K.; Pan, W.; Zhu, M. F. et al. Near-infrared-triggered in situ gelation system for repeatedly enhanced photothermal brachytherapy with a single dose. ACS Nano 2018, 12, 9412-9422.
DOI Google Scholar
[133]
Sheng, J.; Wang, X. Y.; Yan, J. J.; Pan, D. H.; Yang, R. L.; Wang, L. Z.; Xu, Y. P.; Yang, M. Theranostic radioiodine-labelled melanin nanoparticles inspired by clinical brachytherapy seeds. J. Mater. Chem. B 2018, 6, 8163-8169.
DOI Google Scholar
[134]
Kim, Y. S.; Brechbiel, M. W. An overview of targeted alpha therapy. Tumor Biol. 2012, 33, 573-590.
DOI Google Scholar
[135]
Targeted Alpha Therapy Working Group. Targeted alpha therapy, an emerging class of cancer agents: A review. JAMA Oncol. 2018, 4, 1765-1772.
DOI Google Scholar
[136]
Sattiraju, A.; Xiong, X. B.; Pandya, D. N.; Wadas, T. J.; Xuan, A.; Sun, Y.; Jung, Y.; Sai, K. K. S.; Dorsey, J. F.; Li, K. C. et al. Alpha particle enhanced blood brain/tumor barrier permeabilization in glioblastomas using integrin alpha-v beta-3-targeted liposomes. Mol. Cancer Ther. 2017, 16, 2191-2200.
DOI Google Scholar
[137]
Shirley, M.; McCormack, P. L. Radium-223 dichloride: A review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. Drugs 2014, 74, 579-586.
DOI Google Scholar
[138]
McGann, S.; Horton, E. R. Radium-223 dichloride: A novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases. Ann. Pharmacother. 2015, 49, 469-476.
DOI Google Scholar
[139]
Piotrowska, A.; Męczyńska-Wielgosz, S.; Majkowska-Pilip, A.; Koźmiński, P.; Wójciuk, G.; Cędrowska, E.; Bruchertseifer, F.; Morgenstern, A.; Kruszewski, M.; Bilewicz, A. Nanozeolite bioconjugates labeled with 223Ra for targeted alpha therapy. Nucl. Med. Biol. 2017, 47, 10-18.
DOI Google Scholar
[140]
Rojas, J. V.; Woodward, J. D.; Chen, N.; Rondinone, A. J.; Castano, C. H.; Mirzadeh, S. Synthesis and characterization of lanthanum phosphate nanoparticles as carriers for 223Ra and 225Ra for targeted alpha therapy. Nucl. Med. Biol. 2015, 42, 614-620.
DOI Google Scholar
[141]
A. Scheinberg, D.; McDevitt, M. R. Actinium-225 in targeted alpha-particle therapeutic applications. Curr. Radiopharm. 2011, 4, 306-320.
DOI Google Scholar
[142]
Cędrowska, E.; Pruszynski, M.; Majkowska-Pilip, A.; Męczyńska- Wielgosz, S.; Bruchertseifer, F.; Morgenstern, A.; Bilewicz, A. Functionalized TiO2 nanoparticles labelled with 225Ac for targeted alpha radionuclide therapy. J. Nanopart. Res. 2018, 20, 83.
DOI Google Scholar
[143]
Sattiraju, A.; Pandya, D.; Wadas, T.; Xiong, X. B.; Sun, Y.; Jung, Y.; Zhao, D. W.; Solingapuram Sai, K.; Li, K.; Mintz, A. Alpha particle enhanced permeabilization of the blood tumor barrier using alpha-v beta-3 (αvβ3) specific nanoparticles. J. Nucl. Med. 2016, 57, 633.
Google Scholar
[144]
Chakraborty, S.; Vimalnath, K. V.; Sharma, K. S.; Rajeswari, A.; Sarma, H. D.; Ningthoujam, R. S.; Vatsa, R.; Dash, A. Synthesis and biological evaluation of holmium-166 Agglomerated iron oxide nanoparticles for treatment of arthritis of knee joints. J. Nucl. Med. 2016, 57, 1105.
Google Scholar
[145]
Cui, L.; Her, S.; Borst, G. R.; Bristow, R. G.; Jaffray, D. A.; Allen, C. Radiosensitization by gold nanoparticles: Will they ever make it to the clinic? Radiother. Oncol. 2017, 124, 344-356.
DOI Google Scholar
[146]
Raymond, K. N.; Dertz, E. A. Biochemical and physical properties of siderophores. In Iron Transport in Bacteria. Crosa, J. H.; Mey, A. R.; Payne, S. M., Eds.; ASM Press: Washington, DC, 2004; pp 3-17.
[147]
Verry, C.; Sancey, L.; Dufort, S.; Le Duc, G.; Mendoza, C.; Lux, F.; Grand, S.; Arnaud, J.; Quesada, J. L.; Villa, J. et al. Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol. BMJ Open 2019, 9, e023591.
DOI Google Scholar
[148]
Bonvalot, S.; Rutkowski, P. L.; Thariat, J.; Carrère, S.; Ducassou, A.; Sunyach, M. P.; Agoston, P.; Hong, A.; Mervoyer, A.; Rastrelli, M. et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): A multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019, 20, 1148-1159.
DOI Google Scholar
Publication history
Copyright
Acknowledgements

Publication history

Received: 10 May 2020
Revised: 17 June 2020
Accepted: 26 June 2020
Published: 16 July 2020
Issue date: November 2020

Copyright

© Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2020

Acknowledgements

The authors acknowledge support from the Nuclear Regulatory Commission under Faculty Development Grant NRC-HQ-84- 14-G-0052 and from the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, Chemical Sciences, Geosciences, and Biosciences Division at LBNL under Contract DE-AC02-05CH11231, during the writing of this review.

Return